



PRESS RELEASE

## Warrant holders exercise all warrants in Lipidor's incentive program 2018/2021

**STOCKHOLM, Sweden, 19 October 2021** – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company's LTI 2018/2021, which was addressed to CEO Ola Holmlund and Senior Scientist Vibhu Rinwa and which includes 580,000 warrants, with an exercise period during the period 1 - 30 October 2021, has been terminated and that all warrants have been exercised. The exercise price amounted to SEK 2 per share, meaning that Lipidor, through the share subscription, will receive SEK 1.16 million.

On 10 September 2018, the Board of Lipidor decided, with the authorization of the Annual General Meeting, to issue 580,000 warrants to the Company's CEO Ola Holmlund and Senior Scientist Vibhu Rinwa within the framework of a warrant program ("LTI 2018/2021"). Lipidor announces today that all warrants in LTI 2018/2021 have been exercised for subscription of new shares in the Company. To finance the share subscription, the option holders have sold 150,000 warrants to an individual long-term investor. These transferred warrants have also been exercised.

Through the exercise, the number of shares and votes in the Company will increase by 580,000 and the number of shares in the Company will thus amount to 29,976,863 shares, amounting to a dilution of 2%.

### Information

*The information was provided for publication through the office of Lipidor's CEO on 19 October 2021 at 4.30pm (CEST).*

### For more information, please contact:

Ola Holmlund, CEO  
Telephone: +46 (0)72 50 70 369  
Email: [ola.holmlund@lipidor.se](mailto:ola.holmlund@lipidor.se)

### Certified Adviser

Erik Penser Bank AB  
Telephone: +46 (0)8 463 80 00  
E-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

### About AKVANO®

AKVANO® is an innovative water-free and sprayable technology for the formulation of drugs and is particularly suitable for local application to, for example, the skin. AKVANO® is made up of carefully selected lipids which, together with a volatile solvent, constitute carriers of selected active substances. By combining different lipids, AKVANO® can be optimized to achieve the desired function of active components in the formulation. When applied to the skin, the solvent evaporates, and a thin lipid layer is formed on the skin surface for effective release of the active substance.

### About Lipidor



## **PRESS RELEASE**

Lipidor AB (publ) ([www.lipidor.se](http://www.lipidor.se)) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.